Loading
PDBj
✖
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

30GY

Structure of carbamoylated Ser198 recombinant human butyrylcholinesterase upon reaction with (1-benzylpyrrolidin-3-yl)methyl o-tolylcarbamate

This is a non-PDB format compatible entry.
Summary for 30GY
Entry DOI10.2210/pdb30gy/pdb
DescriptorCholinesterase, SULFATE ION, alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (11 entities in total)
Functional Keywordsbutyrylcholinesterase, inhibitor, complex, hydrolase
Biological sourceHomo sapiens (human)
Total number of polymer chains1
Total formula weight63547.14
Authors
Brazzolotto, X.,Mastnak-Sokolov, P.,Kozak, U.,Gobec, S.,Nachon, F. (deposition date: 2026-04-24, release date: 2026-10-07, Last modification date: 2026-11-04)
Primary citationMastnak-Sokolov, P.,Kosak, U.,Meden, A.,Knez, D.,Zakelj, S.,Horvat, S.,Pislar, A.,Kljun, J.,Igert, A.,Dias, J.,Nachon, F.,Brazzolotto, X.,Novak, M.,Rydlova, V.,Karasova, J.Z.,Soukup, O.,Manik, A.,Detka, J.,Salat, K.,Gobec, S.
Structure-Guided Design of a Brain-Penetrant Covalent Inhibitor of Human Butyrylcholinesterase with In Vivo Procognitive Efficacy.
J.Med.Chem., 69:22506-22538, 2026
Cited by
PubMed Abstract: Butyrylcholinesterase (BChE) has emerged as a validated therapeutic target for the management of Alzheimer's disease symptoms, particularly in advanced stages when acetylcholinesterase activity declines. Despite the numerous BChE inhibitors reported, only the cymserine derivative bisnorcymserine has progressed to clinical evaluation. Here, we report the design and characterization of a novel selective human BChE (hBChE) inhibitor, N-benzylpyrrolidine carbamate (S)-(+)-14. Kinetic analyses and X-ray crystallography of the hBChE-inhibitor complex confirm a covalent mechanism of inhibition. Compound (S)-(+)-14 demonstrates favorable metabolic stability and achieves brain exposure following intraperitoneal administration in mice. In a scopolamine-induced cognitive impairment model, (S)-(+)-14 improves cognitive performance without causing cholinergic adverse effects or motor deficits. Collectively, these findings identify (S)-(+)-14 as a structurally validated, brain-penetrant covalent hBChE inhibitor and highlight its promise as a lead compound for the treatment of Alzheimer's disease.
PubMed: 42917927
DOI: 10.1021/acs.jmedchem.6c01737
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.35 Å)
Structure validation

263157

PDB entries from 2026-11-18

PDB statisticsPDBj update infoContact PDBjnumon